Novartis describes Rhapsido as oral BTK inhibitor
The note characterizes Rhapsido as an oral Bruton's tyrosine kinase (BTK) inhibitor.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.